New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GERN;HK;HWD;ISRG;MRO;ONTY;THLD;TROX;ZIOP;STRZA;XWES;NFLX From The Last 14 Days
Check below for free stories on GERN;HK;HWD;ISRG;MRO;ONTY;THLD;TROX;ZIOP;STRZA;XWES;NFLX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 22, 2014
16:13 EDTISRGIntuitive Surgical rises after results, first look
Subscribe for More Information
16:06 EDTISRGIntuitive Surgical reports Q2 EPS $2.77, consensus $2.83
Subscribe for More Information
16:00 EDTNFLXOptions Update; July 22, 2014
Subscribe for More Information
15:30 EDTISRGNotable companies reporting after market close
Subscribe for More Information
13:57 EDTISRGEarnings Preview: Intuitive Surgical share price flat over last 12 months
Subscribe for More Information
12:29 EDTNFLXOn The Fly: Midday Wrap
Subscribe for More Information
11:53 EDTNFLXStocks with call strike movement; NFLX DAL
Netflix (NFLX) December 510 call option implied volatility decreased 9% to 34, Delta Air Lines (DAL) January 44 call option implied volatility increased 2% to 44 according to IVolatility.
11:36 EDTISRGIntuitive Surgical July weekly volatility increases into Q2 and outlook
Subscribe for More Information
11:10 EDTNFLXNetflix EU expansion modestly positive for Equinix, InterXion, says Wells Fargo
Subscribe for More Information
10:50 EDTNFLXNetflix retreats, analysts remain cautious as earnings miss estimate
Shares of Netflix (NFLX) are falling after several research firms reiterated their negative outlook on the stock following the company's second quarter results. WHAT'S NEW: Last night, Netflix reported Q2 earnings per share of $1.15, missing the consensus forecast of analysts by 1c, on revenue of $1.15B, which fell short of $1.33B consensus forecast. The company reported Q2 total streaming net additions of 1.69M, growing its total streaming members to just over 50M. The company guided to Q3 EPS of 89c and revenue of $1.22B, missing the consensus forecasts of $1.06 and $1.38B, respectively. The company said it expects Q3 net additions of 3.69M, to grow its membership to 53.74M. ANALYST OPINION: After Netflix reported slightly weaker than expected Q2 results and its Q3 guidance came in slightly below expectations, Jefferies analyst Brian Fitzgerald noted that the company indicated that it could lower its 2015 profit margin guidance. Netflix said its margin outlook will depend on the amount it spends on content, Fitzgerald added. The analyst believes that rising content costs pose a risk to the stock. He increased his price target on the shares to $350 from $300 but kept an Underperform rating on the stock. Also staying cautious on Netflix was research firm Bernstein. After Netflix suggested that its domestic margins may not rise as much as previously thought, the firm thinks the statement implies that either the company's subscriber growth could drop significantly or it may need to invest more in content. Additionally, Bernstein believes that the company's strong international guidance was based on the launch of new markets whose early results are difficult to predict. The outlook for the company's domestic subscription growth is still uncertain, but should become clearer in Q4 or the first quarter of 2015, added Bernstein, which kept a $260 price target and Underperform rating on the stock. Meanwhile, Citigroup continued to have an upbeat outlook on the company's fundamentals and its growth outlook, but kept a Neutral rating on the shares due to the stock's valuation. WHAT'S NOTABLE: A number of firms remained upbeat on Netflix, as Cantor said that the company has several positive catalysts, while JPMorgan called its results solid. Cantor kept a Buy rating on the stock, while JPMorgan reiterated its Overweight rating. PRICE ACTION: In early trading, Netflix fell $19.78, or 4.3% to $432.17.
10:48 EDTNFLXOptions with decreasing implied volatility
Options with decreasing implied volatility: IGT YHOO LYK ATHN CMG SWKS NFLX SHPG SNDK MTG
09:36 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:00 EDTNFLXNetflix price target raised to $500 from $425 at Cantor
Subscribe for More Information
07:57 EDTNFLXNetflix price target raised to $550 from $500 at JPMorgan
Subscribe for More Information
07:17 EDTNFLXNetflix outlook still uncertain, says Bernstein
Subscribe for More Information
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
06:49 EDTNFLXNetflix price target raised to $453 from $410 at Citigroup
Subscribe for More Information
06:31 EDTNFLXNetflix reported solid Q2 results, says Piper Jaffray
Subscribe for More Information
06:18 EDTNFLXNetflix price target raised to $350 from $300 at Jefferies
Subscribe for More Information
July 21, 2014
18:40 EDTNFLXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use